Despite the lower magnitude of anti-tumor activity seen in vitro when IFN-γ was the only Th1 cytokine, for the in vivo study, we chose to omit TNF-α, due to its reputation of unacceptably high toxicity when administered systemically. The gene discussed is IFNG; the disease is neoplasm.